Pure Global AI
NCT06036121Recruiting

A Study of ADRX-0706 in Select Advanced Solid Tumors

A Phase 1a/b Study of ADRX-0706 in Subjects With Select Advanced Solid Tumors
Adcentrx TherapeuticsPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Solid Tumors
Drug/Device/Intervention
ADRX-0706
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Adcentrx Therapeutics
Location
Los Angeles,Grand Rapids,Houston,San Antonio,West Valley City, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Sep 26, 2023
End date
Dec 01, 2026
Enrollment
114 participants
Primary outcome

Incidence of adverse events

Summary

The primary purpose of this study is to assess the safety, tolerability, and
 pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select
 advanced solid tumors.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm of other connective and soft tissueCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Parametrium
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06036121
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06036121 through Pure Global AI's free database. This Phase 1 trial is sponsored by Adcentrx Therapeutics and is currently Recruiting. The study focuses on Solid Tumors. Target enrollment is 114 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.